Loading stock data…
Evercore Inc. (EVR)
$295.67-2.25 (-0.76%)
Market ClosedLast close Sep 8
Evercore Inc., together with its subsidiaries, operates as an independent investment banking firm in the Americas, Europe, Middle East, Africa, and Asia-Pacific.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Evercore Inc. in the Financial Services sector is trading at $295.67 with a market capitalization of $12.0B. Wall Street consensus targets $363.90 (10 analysts), implying a +23.1% move over the next 12 months. The stock is currently 24% below its 52-week high of $388.71, remaining 9.9% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +23.1% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $1.39B↑ | $1.29B↑ | $1.04B↑ | $833.83M |
| Gross Profit | — | — | — | — | — |
| Operating Income | — | — | — | — | — |
| Net Income | — | $301.24M↑ | $203.95M↑ | $144.58M↑ | $97.20M |
Peer Comparison
JPMBACGS
Fundamentals
Evercore Inc., together with its subsidiaries, operates as an independent investment banking firm in the Americas, Europe, Middle East, Africa, and Asia-Pacific. The company operates through two segments, Investment Banking & Equities, and Investment...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$12.02B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
16.89
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.50
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
1.15%
ROE
Elite ROE. Management converts capital into profit efficiently.
36.46%
Volume
Today's trading volume
397,413
Recent News
Houlihan Lokey Down 21% YTD: Buy the Dip or Stay Cautious?
HLI's 21% YTD slide reflects weaker Corporate Finance and tech deals, while record backlog and diversification offer potential support for a rebound.
Evercore expects softer third-quarter investment banking and trading guidance
Evercore said third-quarter capital markets indicators are tracking below expectations, with the firm anticipating investment banking and trading guidance from banks to come in below consensus estimates. In its August 2026 Capital Markets Monthly report, Evercore said investment banking volumes declined 6% year over year in July as lower debt capital markets activity offset increases in equity capital markets and mergers and acquisitions.
Street Calls of the Week
Monday - Lumentum Holdings What’s the full story? Evercore initiates Lumentum Lumentum Holdings Inc (NASDAQ:LITE) at Outperform with an $1,100 target. The AI revolution has a supply-chain coronary: silicon processors run fast, but data can’t move between them. Connecting these compute clusters requires Indium Phosphide lasers—a scarce, capital-intensive material where demand outpaces supply by 30%. LITE holds the choke point, shifting pricing power and margin upstream to vertically integrated in
Will Evercore’s (EVR) New EMEA Healthcare Hire Subtly Recast Its Advisory Edge in Europe?
Evercore recently announced that John Pissanos has joined the firm as a senior managing director in its healthcare investment banking group, based in London and focusing on life science tools, diagnostics, and medtech. His move from J.P. Morgan, where he led EMEA life science tools and diagnostics, adds specialized sector expertise that could deepen Evercore’s healthcare advisory capabilities in Europe. We’ll now examine how adding a senior EMEA healthcare banker like John Pissanos may...
Is Evercore (EVR) A Bargain On Its Healthcare Banking Hire?
How Evercore’s New Healthcare Hire Connects To The Stock Evercore (EVR) recently appointed John Pissanos as a senior managing director in its healthcare investment banking group, focusing on life science tools, diagnostics and medtech from a London base. Pissanos brings nearly 15 years of investment banking experience, most recently at J.P. Morgan as head of EMEA life science tools and diagnostics. His addition broadens Evercore’s senior coverage in a sector where specialist expertise often...